ArticleBMC endocrine disorders2026
Association of ABO and Rh blood groups with clinicopathological features and lymph node involvement in surgically treated thyroid malignancies: a retrospective single-center study.
Article in BMC endocrine disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study investigated the association between ABO and Rh blood group antigens and the clinicopathological features of 418 patients who underwent thyroidectomy for primary thyroid malignancy between December 2016 and June 2023. Since continuous variables did not follow a normal distribution (p < 0.05), data were presented as median and interquartile range (IQR). The distribution of ABO blood groups was A (44.5%), O (31.8%), B (16.0%), and AB (7.7%), with 90.9% of patients being Rh-positive. The median age of the cohort was 48 years (IQR: 19). While ABO groups showed no significant difference in age, Rh-negative patients were significantly older than Rh-positive patients (52.5 vs. 48.0 years; p = 0.027). No direct association was identified between ABO groups and the overall clinicopathological features such as tumor size or multifocality (p > 0.05). However, significant differences were observed regarding pathologically confirmed lymph node (LN) involvement. Pathologically confirmed LN involvement was significantly more prevalent in the Rh-negative group compared to the Rh-positive group (15.8% vs. 5.5%; p = 0.027). Most notably, a subgroup analysis revealed that patients with the AB blood group had a significantly higher rate of pathologically confirmed LN involvement compared to non-AB groups (15.6% vs. 5.7%; p = 0.028). To confirm the independence of this association, a multivariable logistic regression analysis was performed. After adjusting for potential confounders including age and tumor size, the AB blood group was independently associated with pathologically confirmed LN metastasis in an exploratory multivariable model (OR: 3.114, 95% CI: 1.085-8.938, p = 0.035). These findings suggest that while ABO and Rh blood groups are not significantly associated with most clinicopathological variables in this cohort, they demonstrate specific correlations with nodal disease. These findings may represent exploratory signals that warrant further validation, rather than clinically applicable biomarkers at this stage. Further multicenter prospective studies are warranted to validate these associations across all histological subtypes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.